Pharmaceutical News

RSS

Metformin therapy may protect PCOS women against endometrial cancer

Research led by Warwick Medical School at the University of Warwick has found that Metformin, a drug treatment used to treat diabetes and also in women with Polycystic vary syndrome, may potentially provide protection against endometrial cancer.

5 Apr 2011

$Ranolazine is an effective treatment for patients with refractory angina$

Ranolazine is an effective treatment for patients with refractory angina

Ranolazine is an effective anti-anginal therapy in patients with refractory angina; however, at one year only 59 percent of patients remained on the drug, according to a scientific poster that will be presented at the American College of Cardiology Scientific Sessions in New Orleans, April 1-3.

5 Apr 2011

Artemisinin or high-pressure oxygen can boost natural cancer remedy

A technique Michael Jackson reportedly used to prolong his youth is showing promise as a way to boost the effectiveness of a natural cancer remedy.

5 Apr 2011

Acamprosate can help treat patients with autism, Fragile X syndrome

In small, early clinical trials, adults and children with autism and Fragile X syndrome have shown improved communication and social behavior when treated with acamprosate, according to Craig Erickson, M.D., assistant professor of psychiatry at the Indiana University School of Medicine and chief of the Riley Hospital for Children Christian Sarkine Autism Treatment Center at Indiana University Health.

5 Apr 2011

Nicotine has no effect on lung cancer tumor incidence, frequency or size

Nicotine at doses similar to those found in most nicotine replacements therapies did not increase lung cancer tumor incidence, frequency or size, according to results of a mouse study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

Researchers develop new cancer treatment

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd have developed a new treatment for cancer which rather than attacking tumours directly, prevents the growth of new blood vessels in tumours, starving them of oxygen and nutrients, thereby preventing their growth.

5 Apr 2011

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Cubist Pharmaceuticals, Inc. today announced that it has entered into a license agreement with Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., which includes a stipulation by the parties requesting dismissal of the lawsuit filed by Cubist in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application filed by TPM with the U.S. Food and Drug Administration for a generic version of CUBICIN.

5 Apr 2011

Statins can help prevent risk of death from pneumonia

Taking statins could help prevent people dying from pneumonia, according to a study by the London School of Hygiene and Tropical Medicine.

5 Apr 2011

Risperdal Consta can reduce risk of hospitalisation in patients with schizophrenia

New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry shows treatment with Risperdal Consta is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period.

5 Apr 2011

Exercise may decrease blood flow and oxygen in hypertensive people

UT Southwestern Medical Center researchers have identified one reason people with hypertension experience an even greater increase in their blood pressure when they exercise, and they've learned how to prevent the rise.

5 Apr 2011

ETI develops extended release SC depot formulation of NSAID drug meloxicam

Encore Therapeutics Inc. has developed a proprietary extended release subcutaneous (SC) depot formulation (ETI-511) of the NSAID drug meloxicam.

5 Apr 2011

Gilead's increase of HIV drugs price unreasonable, says AHF

Today AIDS Healthcare Foundation (AHF), the largest global AIDS organization, blasted the news that Gilead Sciences Inc. increased the prices of several of its top selling products at the beginning of the month. The California-based drug maker increased the price of its biggest seller, HIV treatment Atripla, by 5.1%. Gilead also raised the price of HIV drugs Truvada and Emtriva by 7.9%.

5 Apr 2011

Scientists discover new compounds that may help fight against parasitic diseases

Trypanosomatid parasites cause diseases like African sleeping sickness, Chagas' disease and leishmaniasis. Leishmaniasis affects about 12 million people worldwide, mostly in developing countries. Current drug treatments are inadequate due to drug toxicity and resistance.

5 Apr 2011

Boehringer Ingelheim receives FDA approval for Viramune XR to treat HIV-1 infection

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved Viramune XR extended-release tablets, a one-pill, once-daily formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

5 Apr 2011

Pfizer receives FDA Refusal to File letter for tafamidis to treat Transthyretin Familial Amyloid Polyneuropathy

Pfizer Inc. announced today that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for tafamidis, the company's novel, oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).

4 Apr 2011

KKR affiliate to acquire Pfizer's Capsugel business

Pfizer and Kohlberg Kravis Roberts & Co L.P. (together with its affiliates, "KKR") today announced they have entered into an agreement whereby an affiliate of KKR will acquire Pfizer's Capsugel business for $2.375 billion in cash. Capsugel, the world leader in hard capsules and an innovator in drug-delivery systems, generated approximately $750 million in revenue and manufactured more than 180 billion hard capsules in 2010.

4 Apr 2011

Orexo partner ProStrakan launches Abstral in the US

Orexo AB announces today that its partner ProStrakan Group plc has launched Abstral in the United States.

4 Apr 2011

Mylan receives FDA approval for generic Xalatan Ophthalmic Solution

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Latanoprost Ophthalmic Solution, 0.005%, the generic version of Pharmacia and Upjohn's Xalatan® Ophthalmic Solution, an eyedrop that lowers pressure in the eye.

4 Apr 2011

Aspirin usage associated with decrease in pancreatic cancer risk

The use of aspirin at least once per month is associated with a significant decrease in pancreatic cancer risk, according to results of a large case-control study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

BUSPH, The Partnership at Drugfree.org collaborate to increase 'Join Together' resource utilization

The Partnership at Drugfree.org, in cooperation with the Boston University School of Public Health, announced today that Join Together has become part of the 25-year-old nonprofit organization based in New York City.

4 Apr 2011